RVL Pharmaceuticals plc

Good morning, everyone. My name is Brittany, and I will be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals First Quarter 2022 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star 1 on your telephone keypad.

Thank you, operator. Welcome to RVL Pharmaceuticals First Quarter 2022 Financial Results and Commercial Update Call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison, Chief Operating Officer, J.D. Shav, and Interim Chief Financial Officer, Mike DePetris. This morning, the company issued a press release detailing financial results for the three months ended March 31st, 2022. This press release and a webcast of this call can be accessed through the investor section of the RVL website at rvlpharma.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based upon information available to RVL's management as of today and involve risks and uncertainties, including those noted in the press release and our filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. During this call, we may refer to non-GAAP financial measures such as adjusted EBITDA. For reconciliation of adjusted EBITDA to net income or loss from continuing operations, please see the tables at the end of today's press release. The archived webcast of this call will be available for one year on RVL's website, rvlpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on Thursday, May 12, 2022. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to RVL CEO, Brian Markeson.

Good morning, and thank you for joining our call today. We're off to a great start with the first quarter behind us. We continue to grow in line with our plan. Through the end of last week, We have activated over 1,600 accounts, with our second quarter plan continuing to open new accounts and drive utilization or depth from recently opened accounts to generate a reorder cadence that we plan to report on in the future. The recent award we received from Shape Magazine adds to the mounting evidence of social proof and joins awards and or mentions from the likes of Vogue, Elle, Allure, New Beauty, and People, to name a few. As we look ahead, we plan to increase the aesthetic sales team at the beginning of Q3, expand a small inside sales and customer service group, and increase our educational presence in aesthetics, all within the expense guidance we have previously discussed. As we continue to build the eye care and aesthetics markets, we are confident that the growth levers are clear, and most importantly, the efficacy and safety of APNIC continue to drive patient and provider satisfaction. Now, it's important to keep in mind a few things. First, as we create a market in eye care and aesthetics, we have no competition and are not defined by market share in a category. we are our own category. And second, the safety and efficacy of NIEC combined with an attractive margin profile have and will see rapid and widespread utilization for those patients who have droopy eyelids or blepharoptosis. Now I'd like to turn the call over to Mike DePetris, who after joining our team in January in a consulting capacity assumed the interim CFO role in mid-April following Andy's departure. Now just shy of a month into the role, Mike's been coming up to speed, and we'll cover our Q1 financial results in some depth. Mike?